AstraZeneca Plc started late-stage trials for an antibody medicine against Covid-19 after President Donald Trump credited a similar therapy with aiding his recovery.
Eli Lilly & Co. and Regeneron Pharmaceuticals Inc. last week asked the U.S. Food and Drug Administration for emergency-use authorizations but haven’t yet received clearance.
Trump has said Regeneron’s antibody cocktail was key to his apparent recovery from coronavirus. GlaxoSmithKline Plc and Vir Biotechnology Inc.
also started advanced tests on a possible antibody treatment last week."AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to.